CZ776486A3 - Process for preparing heterologous protein within a transformed cell - Google Patents

Process for preparing heterologous protein within a transformed cell

Info

Publication number
CZ776486A3
CZ776486A3 CS867764A CS776486A CZ776486A3 CZ 776486 A3 CZ776486 A3 CZ 776486A3 CS 867764 A CS867764 A CS 867764A CS 776486 A CS776486 A CS 776486A CZ 776486 A3 CZ776486 A3 CZ 776486A3
Authority
CZ
Czechia
Prior art keywords
heterologous protein
transformed cell
preparing heterologous
preparing
transformed
Prior art date
Application number
CS867764A
Other languages
Czech (cs)
Inventor
Vivian L Mackay
Original Assignee
Vivian L Mackay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivian L Mackay filed Critical Vivian L Mackay
Publication of CZ776486A3 publication Critical patent/CZ776486A3/en
Publication of CZ284251B6 publication Critical patent/CZ284251B6/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CS867764A 1985-10-25 1986-10-27 Dna structure comprising a part saccharomyces cerevisiae of bar1 gene, transformed cell containing such structure and process for preparing heterologous protein within the transformed cell CZ284251B6 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79130585A 1985-10-25 1985-10-25
PCT/US1986/002198 WO1987002670A1 (en) 1985-10-25 1986-10-20 Method of using bar1 for secreting foreign proteins

Publications (2)

Publication Number Publication Date
CZ776486A3 true CZ776486A3 (en) 1996-09-11
CZ284251B6 CZ284251B6 (en) 1998-10-14

Family

ID=25153298

Family Applications (1)

Application Number Title Priority Date Filing Date
CS867764A CZ284251B6 (en) 1985-10-25 1986-10-27 Dna structure comprising a part saccharomyces cerevisiae of bar1 gene, transformed cell containing such structure and process for preparing heterologous protein within the transformed cell

Country Status (13)

Country Link
EP (1) EP0243465A1 (en)
JP (1) JP2523562B2 (en)
CN (1) CN1027179C (en)
AU (2) AU6543286A (en)
CA (1) CA1316133C (en)
CZ (1) CZ284251B6 (en)
DK (1) DK320287A (en)
FI (1) FI872801A (en)
HU (1) HU206897B (en)
IE (1) IE63822B1 (en)
SK (1) SK279041B6 (en)
UA (1) UA41863C2 (en)
WO (1) WO1987002670A1 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK58285D0 (en) * 1984-05-30 1985-02-08 Novo Industri As PEPTIDES AND MANUFACTURING AND USING THEREOF
AU2334088A (en) * 1987-10-02 1989-05-18 Zymogenetics Inc. Bar1 secretion signal
US5206699A (en) * 1988-05-06 1993-04-27 Gersan Establishment Sensing a narrow frequency band of radiation and gemstones
EP0387319B1 (en) * 1988-07-23 1996-03-06 Delta Biotechnology Limited Secretory leader sequences
JPH05505308A (en) * 1990-03-13 1993-08-12 ハワイ・バイオテクノロジー・グループ・インコーポレイテツド Blue bread mold expression system
DK82893D0 (en) * 1993-07-08 1993-07-08 Novo Nordisk As PEPTIDE
CN102080070B (en) 1995-03-17 2016-01-20 诺沃奇梅兹有限公司 new endoglucanase
DK1975177T3 (en) 1996-03-01 2011-07-25 Novo Nordisk As Appetite suppressant peptide, formulations thereof and use thereof
CA2395713C (en) 2000-01-10 2012-04-10 Torben Lauesgaard Nissen G-csf conjugates
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
IL156059A0 (en) 2001-02-27 2003-12-23 Maxygen Aps NEW INTERFERON beta-LIKE MOLECULES
BR0208203A (en) 2001-03-22 2005-04-19 Novo Nordisk Healthcare Ag Factor vii polypeptide, factor vii derivative, composition, pharmaceutical composition, polynucleotide construction, eukaryotic host cell, transgenic animal, transgenic plant, and methods for producing factor vii polypeptide and a factor vii derivative, use of a derivative of vii, methods for treating bleeding episodes or bleeding disorders in a patient or for enhancing the normal hemostatic system and inhibiting thrombus formation in a patient
US6534059B2 (en) 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
WO2003027147A2 (en) 2001-09-27 2003-04-03 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
CN101870729A (en) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 Coagulation factor vii polypeptides
JP2008538290A (en) 2005-04-18 2008-10-23 ノボ ノルディスク アクティーゼルスカブ IL-21 mutant
WO2007020256A1 (en) 2005-08-16 2007-02-22 Novo Nordisk A/S Method for making mature insulin polypeptides
EP2316930A1 (en) 2005-09-14 2011-05-04 Novo Nordisk Health Care AG Human coagulation factor VII polypeptides
WO2007103447A2 (en) 2006-03-06 2007-09-13 Humagene, Inc. A method for the preparation of recombinant human thrombin
AU2007292903B2 (en) 2006-09-08 2012-03-29 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
JP5503968B2 (en) 2006-09-27 2014-05-28 ノボ・ノルデイスク・エー／エス Method for producing mature insulin polypeptide
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
WO2010103038A1 (en) 2009-03-11 2010-09-16 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
KR101870378B1 (en) 2009-07-17 2018-06-25 릭스하스피탈렛 Masp isoforms as inhibitors of complement activation
ES2583259T3 (en) 2009-12-01 2016-09-20 Novo Nordisk A/S New alpha-amidant peptidyl alpha-hydroxyglycine liases
JP2013515080A (en) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド Modified bovine somatotropin polypeptides and their use
AU2010341518B2 (en) 2009-12-21 2014-01-09 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
EP3815708A1 (en) 2010-03-05 2021-05-05 Omeros Corporation Chimeric inhibitor molecules of complement activation
US20110229921A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
US9551714B2 (en) 2010-06-25 2017-01-24 Abbott Laboratories Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies
SG10201506443TA (en) 2010-08-17 2015-10-29 Ambrx Inc Modified relaxin polypeptides and their uses
TWI480288B (en) 2010-09-23 2015-04-11 Lilly Co Eli Formulations for bovine granulocyte colony stimulating factor and variants thereof
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
EP2649178B8 (en) 2010-12-09 2017-08-30 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
MX349562B (en) 2011-12-09 2017-08-02 Pasteur Institut Multiplex immuno screening assay.
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
BR112014018630A2 (en) 2012-02-09 2017-07-04 Var2 Pharmaceuticals Aps bleaching of chondroitin sulfate glycans
US20150307865A1 (en) 2012-10-15 2015-10-29 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
JP2014128262A (en) * 2012-11-27 2014-07-10 Kirin Brewery Co Ltd Screening method for yeast strains having conjugative ability
MX2020011529A (en) 2018-05-01 2021-01-29 Ambrx Inc A method for optimizing antibody expression.
EP3821244A1 (en) 2018-07-13 2021-05-19 Varct Diagnostics ApS Isolation of circulating cells of fetal origin using recombinant malaria protein var2csa
DK3849614T3 (en) 2018-09-11 2024-02-26 Ambrx Inc INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND USES THEREOF
JP2022512746A (en) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド Interleukin-10 polypeptide complex, its dimer, and their use
KR20210136014A (en) 2019-02-12 2021-11-16 암브룩스, 인코포레이티드 Compositions, methods and uses thereof containing antibody-TLR agonist conjugates
KR20220151202A (en) 2020-03-11 2022-11-14 암브룩스, 인코포레이티드 Interleukin-2 polypeptide conjugates and methods of use thereof
EP4136459A1 (en) 2020-04-13 2023-02-22 Abbott Laboratories Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample
WO2022031804A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Improved methods and kits for detecting sars-cov-2 protein in a sample
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
AU2022249223A1 (en) 2021-04-03 2023-10-12 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
CN115806889B (en) * 2022-09-28 2024-06-11 山东大学 Saccharomyces cerevisiae engineering bacteria for improving gene expression level and construction method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4613572A (en) * 1983-08-15 1986-09-23 Kansas State University Research Foundation Yeast BAR1 gene plasmid
DE3537176C2 (en) * 1984-10-18 1994-06-09 Zymogenetics Inc Tissue plasminogen activator and process for its manufacture
JPS61247384A (en) * 1984-10-18 1986-11-04 チモ−ジエネテイツクス　インコ−ポレ−テツド Development of plasminogen activating factor in yeast

Also Published As

Publication number Publication date
DK320287D0 (en) 1987-06-23
JP2523562B2 (en) 1996-08-14
SK776486A3 (en) 1998-06-03
UA41863C2 (en) 2001-10-15
SK279041B6 (en) 1998-06-03
CA1316133C (en) 1993-04-13
FI872801A0 (en) 1987-06-24
EP0243465A1 (en) 1987-11-04
HUT43624A (en) 1987-11-30
AU676132B2 (en) 1997-03-06
CZ284251B6 (en) 1998-10-14
IE63822B1 (en) 1995-06-14
AU6543286A (en) 1987-05-19
CN86107554A (en) 1987-08-26
JPS63501614A (en) 1988-06-23
IE862804L (en) 1987-04-25
DK320287A (en) 1987-06-23
WO1987002670A1 (en) 1987-05-07
HU206897B (en) 1993-01-28
AU7400391A (en) 1991-07-18
FI872801A (en) 1987-06-24
CN1027179C (en) 1994-12-28

Similar Documents

Publication Publication Date Title
CZ776486A3 (en) Process for preparing heterologous protein within a transformed cell
IL78960A0 (en) Method for preparing infectionresistant materials
NZ221790A (en) Method for the continuous production of a heterologous protein in a eukaryotic host cell
GR861583B (en) Method for preparing new 2-arylimidazolines
HUT40567A (en) Process for preparing stable nicorandyl preparations
PT82805A (en) Process for preparing a gasoline composition
ZA862929B (en) Process for preparing(z)-1-phenyl-1-diethylaminocarbonyl-2-aminomethyl-cyclopropane hydrochloride
GB2160870B (en) Process for preparing peptides
EP0199997A3 (en) Process for preparing diaryl-pentaerythritol
PT83078A (en) Process for preparing phenylpiperazine phosphonates
GB2163036B (en) Process for preparing tofu charged into a container
CS690485A2 (en) Process for preparing aminoalcohols
PT83293B (en) Process for preparing dihidropyridine-2-hydroxyamines useful asmedicaments
PT83154A (en) Process for preparing quinolizinesulphonamides
HUT37804A (en) Process for preparing peptides
HUT42766A (en) Process for preparing n-sulfamyl-3-(2-guanidino-thiazolyl-4-methyl-thio)-propionamidine
ZA863454B (en) Process for preparing benzothiazolesulphenamides
PT83654A (en) Process for preparing difluorocyclostatine containing polypeptides
DE3666034D1 (en) Process for preparing alkenylaromatic compounds
CS435886A2 (en) Process for preparing 2-brom-alfa-ergokryptine
HUT43022A (en) Process for preparing monochloro-pinacolone
DE3660868D1 (en) Process for preparing ethyl-alpha-(1-carboxyethyl)-amino-gamma-oxo-gamma-phenylbutyrate
HUT42769A (en) Process for preparing pyridazodiazepines
HUT43039A (en) Process for preparing 4-hydroxy-2-oxo-pyrrolidin-1-yl-acetamide
GB2163035B (en) Process for preparing tofu charged into a container

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20041027